ABC008-IBM-202
Brief description of study
A Long-Term Extension study for patients who have completed the double-blind treatment trial ABC008-IBM-201. The primary objective is to assess the long-term safety and tolerability of ulviprubart (ABC008) in subjects with Inclusion Body Myositis, as well as to assess long-term efficacy using a standardized weight-based dose (2.0 mg/kg) previously evaluated as part of the double-blind trial.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
